FROVA
Clinical safety rating
cautionComprehensive clinical and safety monograph for FROVA (FROVA).
Selective serotonin 5-HT1B/1D receptor agonist; causes vasoconstriction of cranial arteries and inhibits trigeminal nerve transmission.
| Metabolism | Hepatic via CYP1A2; primary metabolite is 5-hydroxyfrovatriptan. |
| Excretion | Primarily hepatic metabolism followed by renal and fecal elimination. Approximately 62% of the dose is recovered in urine (mainly as metabolites, <10% unchanged) and 32% in feces. |
| Half-life | Terminal elimination half-life is 26 hours. This prolonged half-life supports once-daily dosing and provides sustained headache relief. |
| Protein binding | Approximately 15% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | Volume of distribution (Vd) is approximately 2.4 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral bioavailability is approximately 30% due to first-pass metabolism. |
| Onset of Action | Oral: Onset of headache relief occurs within 30–60 minutes after a single 2.5 mg dose. |
| Duration of Action | Duration of effect is approximately 24 hours based on headache recurrence data, allowing once-daily dosing for migraine prophylaxis. |
| Molecular Weight | 244.25 |
2.5 mg orally once daily; maximum 5 mg/day.
| Dosage form | TABLET |
| Renal impairment | No adjustment required for GFR ≥30 mL/min; use not recommended for GFR <30 mL/min. |
| Liver impairment | Contraindicated in severe hepatic impairment (Child-Pugh C); use with caution in moderate impairment (Child-Pugh B) at reduced dose (2.5 mg every other day). |
| Pediatric use | Not approved for use in pediatric patients; safety and efficacy not established. |
| Geriatric use | No specific dose adjustment, but monitor for increased sensitivity and renal function due to age-related decline. |
| 1st trimester | Avoid; associated with fetal cardiovascular defects and orofacial clefts due to NSAID-like COX inhibition. |
| 2nd trimester | Use only if benefit outweighs risk; may cause oligohydramnios and premature ductus arteriosus constriction. |
| 3rd trimester | Contraindicated due to high risk of premature closure of ductus arteriosus and oligohydramnios. |
Clinical note
Comprehensive clinical and safety monograph for FROVA (FROVA).
| Placental transfer | Crosses placenta; detected in fetal plasma and amniotic fluid. |
| Breastfeeding | Excreted into breast milk in low amounts; caution due to potential adverse effects on infant cardiovascular system. |
| Lactation Rating | L3 (Limited data; caution advised) |
| Teratogenic Risk | Frovatriptan is contraindicated in pregnancy due to potential fetal harm. In animal studies, frovatriptan was associated with reduced fetal weights and increased incidence of fetal abnormalities at maternal toxic doses. In humans, there is no adequate data; however, triptans as a class may increase risk of preterm delivery, low birth weight, and possibly orofacial clefts when used in the first trimester. Use during first trimester: Risk category not formally assigned but should be avoided. Second and third trimesters: Avoid due to potential for uterine contractions and reduced placental perfusion. Labor and delivery: Contraindicated as it may cause uterine hypertonicity and fetal distress. |
| Fetal Monitoring | If unintentionally exposed during pregnancy, monitor fetal growth via serial ultrasounds (assess for IUGR), assess for preterm labor signs, and fetal heart rate monitoring if used near term. Monitor maternal blood pressure and signs of serotonin syndrome if used with other serotonergic drugs. |
| Fertility Effects | No specific data on human fertility impairment. Animal studies showed no adverse effects on fertility at exposures up to 100 times the MRHD. However, triptans may theoretically affect ovarian blood flow; use in women attempting conception should be minimized in favor of safer alternatives. |
■ FDA Black Box Warning
Do not use in patients with ischemic heart disease, coronary artery vasospasm, or other significant cardiovascular conditions.
| Serious Effects |
Severe hepatic impairmentSevere uncontrolled hypertensionIschemic heart diseaseHistory of myocardial infarction or strokeHemiplegic or basilar migraineConcurrent use of ergotamine derivativesHypersensitivity to frovatriptan
| Precautions | Risk of myocardial ischemia, cerebral hemorrhage, cardiac arrhythmias; serotonin syndrome with concomitant serotonergic drugs; medication overuse headache; severe hepatic impairment. |
| Food/Dietary | No significant food interactions. Grapefruit juice does not affect frovatriptan metabolism. Avoid alcohol during migraine attacks as it may worsen headache or increase drowsiness. |
| Clinical Pearls | Frovatriptan has the longest half-life (~26 hours) among triptans, which may be beneficial for patients with prolonged migraine attacks or frequent recurrence. Onset of action is slower (~2-4 hours) compared to sumatriptan. Use with caution in patients with cardiovascular risk factors due to vasoconstrictive effects. Contraindicated within 24 hours of other triptans or ergotamine-containing medications. |
| Patient Advice | Take FROVA at the first sign of a migraine headache, but it can be taken any time during an attack. · Do not exceed one tablet (2.5 mg) in a 24-hour period; if headache returns, repeat dose after at least 2 hours. · Do not take within 24 hours of another triptan or ergotamine-type medication. · Common side effects include dizziness, fatigue, tingling, and flushing. Report chest tightness, palpitations, or shortness of breath immediately. · Seek emergency care if headache worsens or is accompanied by stiff neck, fever, or vision changes. · Inform your doctor if you have heart disease, high blood pressure, liver disease, or are pregnant or breastfeeding. |
Loading safety data…